Clinical trial attrition remains punishing, yet regulators still approved 55 new drugs in 2023 through the FDA alone. Across the same year, the EMA cleared 38 novel medicines, while FDA oncology approvals reached 15. These approval streaks land alongside a patent cliff that forces faster decisions on development, launches, and portfolio planning.
Key Takeaways
- FDA approved 55 new drugs in 2023
- Pharma industry employed 5.5 million people globally in 2023
- Global pharmaceutical market size reached $1.63 trillion in 2023
- R&D spending by pharma industry was $213 billion in 2022
- Pfizer sales reached $58.5 billion in 2023
Pharma industry statistics show steady growth driven by rising demand for innovative treatments worldwide.
Related reading
01 · Category
Drug Development and Approvals22 stats
01
FDA approved 55 new drugs in 2023
02
EMA approved 38 novel medicines in 2023
03
Oncology drugs approvals reached 15 by FDA in 2023
04
Gene therapy approvals hit 8 globally in 2023
05
Biosimilar approvals by FDA totaled 7 in 2023
06
Orphan drug approvals were 25 by FDA in 2023
07
Cell therapy approvals reached 4 by FDA in 2023
08
First-in-class drug approvals were 20 by FDA in 2023
09
PMDA Japan approved 12 new molecular entities in 2023
10
China NMPA approved 88 new drugs in 2023
11
Global Phase III trials active numbered 5,200 in 2023
12
Biologics approvals accounted for 40% of FDA new drugs in 2023
13
Rare disease approvals globally hit 100 in 2023
14
Vaccine approvals were 5 by FDA in 2023
15
ADC drug approvals reached 3 in 2023
16
mRNA approvals beyond COVID were 2 in 2023
17
Clinical trials registered globally 45,000 in 2023
18
Success rate from Phase I to approval 10% in 2023 data
19
Accelerated approvals by FDA 12 in 2023
20
New chemical entities approved 37 by FDA in 2023
21
Pharma pipeline drugs totaled 18,000 in 2023
22
BLA approvals by FDA 15 in 2023
Interpretation
Drug Development and Approvals Interpretation
Despite a sobering 90% attrition rate in clinical trials, the industry's pipeline is a hive of activity, delivering a record-breaking harvest of highly specialized, often first-of-their-kind therapies—from precision oncology drugs and gene therapies to orphan drugs and biosimilars—proving that while the odds of bringing a new drug to market are daunting, the global pursuit of medical innovation is both relentless and remarkably fruitful.
02 · Category
Employment and Operations20 stats
01
Pharma industry employed 5.5 million people globally in 2023
02
U.S. pharma workforce totaled 850,000 in 2023
03
PhRMA members employed 900,000 in U.S. in 2023
04
Europe pharma industry jobs 800,000 in 2023
05
India pharma sector employed 3 million in 2023
06
China pharma workforce 2.5 million in 2023
07
Manufacturing jobs in pharma 1.2 million globally in 2023
08
R&D staff in pharma 500,000 worldwide in 2023
09
Sales and marketing roles 40% of pharma workforce in 2023
10
Women comprised 45% of pharma employees in 2023
11
STEM jobs in pharma grew 10% to 300,000 in U.S. 2023
12
Contract manufacturing organizations employed 400,000 in 2023
13
Pharma supply chain workers 2 million globally in 2023
14
Clinical trial staff totaled 250,000 in 2023
15
Regulatory affairs professionals 100,000 worldwide in 2023
16
Pharmacists in industry 150,000 globally in 2023
17
Biotech firms employed 300,000 in U.S. in 2023
18
API manufacturing jobs 500,000 in India/China 2023
19
Digital roles in pharma doubled to 50,000 in 2023
20
Pharma plant capacity utilization 75% globally in 2023
Interpretation
Employment and Operations Interpretation
This immense global ecosystem, where nearly half the army is selling the pill while a quarter million scientists develop it, proves that creating health is a logistical, scientific, and profoundly human endeavor.
03 · Category
Market Size and Revenue30 stats
01
Global pharmaceutical market size reached $1.63 trillion in 2023
02
U.S. pharmaceutical market revenue hit $633 billion in 2023
03
European pharma market valued at $370 billion in 2023
04
Asia-Pacific pharma market grew to $400 billion in 2023
05
Pharma market projected to reach $2.3 trillion by 2028
06
Biopharma segment accounted for 30% of global pharma revenue in 2023
07
Generic drugs market size was $465 billion in 2023
08
OTC pharmaceuticals market reached $183 billion globally in 2023
09
U.S. pharma spending per capita was $1,414in 2022
10
China pharma market grew 7.5% to $170 billion in 2023
11
Japan pharma market size was $110 billion in 2023
12
India pharma market reached $50 billion in FY2023
13
Brazil pharma market valued at $32 billion in 2023
14
Pharma revenue in Germany was $65 billion in 2023
15
UK pharma market size hit $55 billion in 2023
16
Pharma market CAGR expected at 6.1% from 2024-2030
17
Specialty pharma market reached $500 billion in 2023
18
Vaccine market size was $61 billion in 2023
19
Oncology pharma market valued at $223 billion in 2023
20
Diabetes drug market size reached $58 billion in 2023
21
Cardiovascular pharma market was $150 billion in 2023
22
Autoimmune disease drugs market hit $140 billion in 2023
23
Pharma e-commerce market grew to $25 billion in 2023
24
Contract manufacturing pharma market was $140 billion in 2023
25
Biosimilars market size reached $26 billion in 2023
26
Rare disease drugs market valued at $200 billion in 2023
27
Pharma logistics market was $100 billion in 2023
28
Digital health pharma market hit $50 billion in 2023
29
Nutraceuticals market size was $450 billion in 2023
30
Pharma packaging market reached $110 billion in 2023
Interpretation
Market Size and Revenue Interpretation
It appears our collective investment in not dying is not only a booming $1.63 trillion global enterprise but a remarkably precise one, neatly subdivided into ever more specific and expensive hopes.
More related reading
04 · Category
R&D Investment30 stats
01
R&D spending by pharma industry was $213 billion in 2022
02
Pfizer R&D budget was $11.4 billion in 2023
03
Roche invested $15.2 billion in R&D in 2023
04
Johnson & Johnson R&D spend hit $15.1 billion in 2023
05
Merck R&D expenditure was $30.5 billion in 2023
06
Novartis R&D budget reached $11.2 billion in 2023
07
AstraZeneca invested $9.1 billion in R&D in 2023
08
Sanofi R&D spend was $7.3 billion in 2023
09
GSK R&D investment totaled $8.2 billion in 2023
10
Bristol Myers Squibb R&D budget was $9.3 billion in 2023
11
AbbVie R&D expenditure hit $7.7 billion in 2023
12
Eli Lilly R&D spend was $9.7 billion in 2023
13
Biogen invested $4.1 billion in R&D in 2023
14
Amgen R&D budget reached $4.8 billion in 2023
15
Gilead Sciences R&D spend was $5.7 billion in 2023
16
Moderna R&D investment totaled $4.5 billion in 2023
17
Regeneron R&D budget was $4.4 billion in 2023
18
Vertex Pharmaceuticals R&D spend hit $3.6 billion in 2023
19
Takeda R&D expenditure was $5.1 billion in 2023
20
CSL Limited invested $3.2 billion in R&D in 2023
21
Pharma R&D intensity averaged 19% of sales in 2022
22
Biopharma R&D pipeline grew 5% to 20,000 projects in 2023
23
Oncology R&D investment was $85 billion in 2023
24
Cell and gene therapy R&D spend hit $25 billion in 2023
25
AI in pharma R&D market grew to $2 billion in 2023
26
Early-stage R&D accounted for 70% of total pharma R&D in 2023
27
Pharma R&D clinical trial costs averaged $2.6 billion per drug in 2023
28
Venture capital in pharma R&D was $45 billion in 2023
29
Public funding for pharma R&D reached $100 billion globally in 2023
30
Phase III trials consumed 50% of R&D budgets in 2023
Interpretation
R&D Investment Interpretation
This astonishing financial siege—where over $200 billion annually is marshaled against disease, and yet the average drug costs billions to develop—reveals both the staggering price of hope and the profound economic gravity of a cure.
report visual · Key figures
Key Pharma Mix & Success Metrics (2023)
Biopharma and FDA biologics play a major share of approvals, alongside a 10% Phase I-to-approval success rate.
40%
Biologics approvals accounted for 40% of FDA new drugs in 2023
30%
Biopharma segment accounted for 30% of global pharma revenue in 2023
10%
Success rate from Phase I to approval 10% in 2023 data
40%
Sales and marketing roles 40% of pharma workforce in 2023
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Rachel Svensson. (2026, February 13). Pharma Industry Statistics. Gitnux. https://gitnux.org/pharma-industry-statistics
MLA
Rachel Svensson. "Pharma Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/pharma-industry-statistics.
Chicago
Rachel Svensson. 2026. "Pharma Industry Statistics." Gitnux. https://gitnux.org/pharma-industry-statistics.
Sources & references
62 datasets cited across this report · attribution is report-level